Business Wire

Clearwater Analytics: Insurance Investment Outsourcing Hits Record $4.5 Trillion as Insurers Expand Further into Private Markets

Share

2025 Insurance Investment Outsourcing Report Shows 25% Growth as Private Market Assets Surge to $800 Billion

Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today released the 2025 Insurance Investment Outsourcing Report (IIOR). Produced in partnership with DCS Financial Consulting, the report reveals a record $4.5 trillion in unaffiliated general account insurance assets under management (AUM) – up 24% year-over-year. Investment consultant assets under advisement also grew significantly to $2 trillion.

The dramatic growth in insurance investment outsourcing reflects several market forces, including the need for specialized expertise in emerging asset classes, the search for yield in a challenging market environment, and structures and asset classes that address increased regulatory complexity. These factors have created an unprecedented demand for sophisticated investment management technology platforms capable of handling complex multi-asset portfolios.

“Looking back over the last decade of the report, we have seen outsourced AUM almost triple to $4.5 trillion, the number of managers more than double to 90 participants, and private asset class AUM surge from less than $50 billion to over $800 billion,” said Sandeep Sahai, CEO of Clearwater Analytics. “Clearwater recognized the significance of these trends years ago and dedicated resources to build the most comprehensive cloud-native platform for institutional investors across global public and private markets. This transformation requires investment expertise and a robust technology infrastructure to manage increasing multi-asset complexity.”

The global report reveals three key trends that are reshaping insurance investment management:

  • Private Asset Class Expansion: Private asset AUM grew 34% YoY to $800 billion. A decade ago, less than $50 billion was reported in this segment. Private asset class managers are entering the insurance space and insurers are investing. This shift toward private markets demonstrates insurers’ search for yield and portfolio diversification.
  • Multi-Asset Class: While private assets are on the rise, public assets remain the foundation of an insurer’s multi-asset class portfolio. Eighty-three percent of participating managers reported public asset class strategies, with many of them also offering private asset classes. Many now provide both, requiring enhanced operations and robust analytical capabilities.
  • Technology-Driven Solutions are Required: Over 80% of participating managers now provide customized portfolio reporting, cash flow projections, accounting analytics, and regulatory assistance—all powered by advanced technology solutions. AI-driven analytics are gaining traction as data-driven decision-making becomes essential.

Steve Doire, owner of DCS Financial Consulting and Strategic Advisor to Clearwater, highlights the growing role of insurance asset management in institutional asset management. “Insurers are increasingly leveraging external managers for both traditional fixed income and complex alternative assets, including private credit—a shift that was barely visible five years ago. The IIOR serves as a key resource for insurers to identify and research managers with the expertise, asset class strategies, and related services and technology needed to support their investment operations.”

The 2025 IIOR provides detailed profiles of over 100 investment managers and consultants, emerging investment strategies across public and private markets, and expert perspectives on the market’s evolution. This comprehensive resource helps insurers make informed decisions about their investment management strategies and technology requirements.Download the 2025 IIOR today.

About Clearwater Analytics

Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry's most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater's single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $8.8 trillion in assets globally. Learn more at www.clearwateranalytics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250521401859/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye